These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 3087473)

  • 1. Biosynthesis of thromboxane in patients with systemic sclerosis and Raynaud's phenomenon.
    Mikhailidis DP; Hutton RA; Jeremy JY; Dandona P
    Br Med J (Clin Res Ed); 1986 May; 292(6533):1461. PubMed ID: 3087473
    [No Abstract]   [Full Text] [Related]  

  • 2. Biosynthesis of thromboxane in patients with systemic sclerosis and Raynaud's phenomenon.
    Reilly IA; Roy L; Fitzgerald GA
    Br Med J (Clin Res Ed); 1986 Apr; 292(6527):1037-9. PubMed ID: 3083991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Difficulty in detecting reperfusion injury increment in oxidative stress among patients with primary Raynaud's phenomenon and systemic sclerosis.
    Herrick AL; Rieley F; Braganza JM; Jayson MI
    J Rheumatol; 1995 Feb; 22(2):374-5. PubMed ID: 7738971
    [No Abstract]   [Full Text] [Related]  

  • 4. Characterization of endothelin-binding sites in human skin and their regulation in primary Raynaud's phenomenon and systemic sclerosis.
    Knock GA; Terenghi G; Bunker CB; Bull HA; Dowd PM; Polak JM
    J Invest Dermatol; 1993 Jul; 101(1):73-8. PubMed ID: 8331298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Artifactual hypoglycaemia in a patient with scleroderma and Raynaud's phenomenon.
    Osman R; Erasmus E; Lahri S; Moosajee F
    S Afr Med J; 2021 Feb; 111(2):13202. PubMed ID: 33944714
    [No Abstract]   [Full Text] [Related]  

  • 6. Studies of endogenous catecholamines in patients with Raynaud's phenomenon secondary to progressive systemic sclerosis (scleroderma).
    Sapira JD; Rodnan GP; Scheib ET; Klaniecki T; Rizk M
    Am J Med; 1972 Mar; 52(3):330-7. PubMed ID: 4551793
    [No Abstract]   [Full Text] [Related]  

  • 7. Deficiency of calcitonin gene-related peptide in Raynaud's phenomenon.
    Bunker CB; Terenghi G; Springall DR; Polak JM; Dowd PM
    Lancet; 1990 Dec 22-29; 336(8730):1530-3. PubMed ID: 1979366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].
    Serri J; Legré R; Veit V; Guardia C; Gay AM
    Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Responses to nifedipine by patients with Raynaud's disease and Raynaud's phenomenon secondary to another disease.
    Riccio A; Del Puente A; Farinaro C; Scarpa R; Oriente P; Rocco P; Gioia M
    Clin Ther; 1987; 9(2):232-7. PubMed ID: 3568066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Esophageal motility in Raynaud's disease, systemic scleroderma and presclerodermal Raynaud's syndrome].
    Hostein J; Bost R; Carpentier P; Franco A; Fournet J
    Gastroenterol Clin Biol; 1985 Feb; 9(2):130-5. PubMed ID: 3979734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endothelial and adrenergic dysfunction in Raynaud's phenomenon and scleroderma.
    Freedman RR; Girgis R; Mayes MD
    J Rheumatol; 1999 Nov; 26(11):2386-8. PubMed ID: 10555897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cold-induced coronary Raynaud's phenomenon in patients with systemic sclerosis.
    Lekakis J; Mavrikakis M; Emmanuel M; Prassopoulos V; Papazoglou S; Papamichael C; Moulopoulou D; Kostamis P; Stamatelopoulos S; Moulopoulos S
    Clin Exp Rheumatol; 1998; 16(2):135-40. PubMed ID: 9536388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Raynaud's phenomenon and systemic sclerosis.
    Generini S; Kahaleh B; Matucci-Cerinic M; Pignone A; Lombardi A; Ohtsuka T
    Ann Ital Med Int; 1996; 11(2):125-31. PubMed ID: 8974438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma.
    Colakoğlu M; Cobankara V; Akpolat T
    Ann Pharmacother; 2007 Sep; 41(9):1544-7. PubMed ID: 17666574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Raynaud's phenomena: diagnostic and treatment study].
    Priollet P
    Rev Prat; 1998 Oct; 48(15):1659-64. PubMed ID: 9814067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Raynaud's phenomenon and Raynaud's disease definition of Raynaud's phenomenon.
    Pratesi F; Corsi C; Deidda C; Nuti A
    Schweiz Rundsch Med Prax; 1976 Nov; 65(44):1368-70. PubMed ID: 1005332
    [No Abstract]   [Full Text] [Related]  

  • 17. Increased prostacyclin metabolites and decreased red cell deformability in patients with systemic sclerosis and Raynauds syndrome.
    Belch JJ; McLaren M; Anderson J; Lowe GD; Sturrock RD; Capell HA; Forbes CD
    Prostaglandins Leukot Med; 1985 Jan; 17(1):1-9. PubMed ID: 3883365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma beta-thromboglobulin in the differential diagnosis of Raynaud's phenomenon.
    Seibold JR; Harris JN
    J Rheumatol; 1985 Feb; 12(1):99-103. PubMed ID: 2580093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of cold and emotional stress in Raynaud's disease and scleroderma.
    Freedman RR; Ianni P
    Br Med J (Clin Res Ed); 1983 Nov; 287(6404):1499-502. PubMed ID: 6416474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantification of the nail fold capillary abnormalities in systemic sclerosis and Raynaud's syndrome.
    Statham BN; Rowell NR
    Acta Derm Venereol; 1986; 66(2):139-43. PubMed ID: 2424237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.